PYPD
PolyPid Ltd.
1W: -2.3%
1M: +0.9%
3M: +7.8%
YTD: -1.4%
1Y: +44.4%
3Y: -78.2%
5Y: -98.7%
$4.29
+0.21 (+5.15%)
After Hours: $4.59 (+0.30, +6.99%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$43.7M
52W Range2.3-5.12
Volume72,009
Avg Volume64,033
Beta1.55
Dividend—
Analyst Ratings
Company Info
CEODikla Czaczkes Akselbrad
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-26
Websitepolypid.com
18 Hasivim Street
Petah Tikva 4959376
IL
Petah Tikva 4959376
IL
972 7 4719 5700
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest News
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Announces Participation in Upcoming Investor Conferences
PolyPid Q4 Earnings Call Highlights
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Barenholz Yechezkel | 0 | — | 2026-03-18 | |
| Barenholz Yechezkel | 14,440 | $2.67 | 2025-08-12 | |
| BenAmram Joseph | 14,440 | $2.67 | 2025-08-12 | |
| Missulawin Jonathan | 43,000 | $4.64 | 2025-06-09 | |
| Missulawin Jonathan | 28,000 | $2.67 | 2025-06-09 |